Table 3 Logistic regression analyses for secondary outcomes

Dependent variable: BI at discharge ≥ 90

 Edaravone use

1.00

0.89–1.13

0.962

0.91

0.77–1.08

0.274

 Age, per 10 years

0.37

0.34–0.40

<0.001

0.43

0.38–0.47

<0.001

 Male

1.97

1.75–2.20

<0.001

1.56

1.34–1.83

<0.001

 BMI < 20kg/m²

0.49

0.42–0.57

<0.001

0.59

0.49–0.72

<0.001

JCS at admission

 0

reference

reference

 1–3

0.30

0.27–0.34

<0.001

0.35

0.30–0.41

<0.001

 10–30

0.10

0.07–0.13

<0.001

0.13

0.09–0.19

<0.001

 100–300

0.04

0.02–0.11

<0.001

0.07

0.02–0.22

<0.001

 eGFR < 60 mL/min /1.73m² 

0.71

0.62–0.81

<0.001

0.90

0.77–1.06

0.210

 HTN medication at onset

0.83

0.74–0.94

0.004

0.86

0.73–1.02

0.084

 Intravenous drug use^a

0.70

0.60–0.83

<0.001

0.72

0.57–0.89

0.003

Dependent variable: mRS at discharge 0–2

 Edaravone use

1.00

0.90–1.13

0.948

0.91

0.78–1.06

0.215

 Age, per 10 years

0.46

0.42–0.49

<0.001

0.56

0.51–0.61

<0.001

 Male

1.69

1.52–1.89

<0.001

1.30

1.12–1.50

<0.001

 BMI < 20 kg/m²

0.55

0.48–0.64

<0.001

0.69

0.58–0.83

<0.001

JCS at admission

 0

reference

reference

 1–3

0.32

0.28–0.35

<0.001

0.39

0.33–0.45

<0.001

 10–30

0.10

0.08–0.14

<0.001

0.16

0.11–0.22

<0.001

 100–300

0.04

0.02–0.09

<0.001

0.06

0.02–0.15

<0.001

 eGFR < 60 mL/min /1.73m² 

0.72

0.64–0.82

<0.001

0.89

0.77–1.03

0.119

 HTN medication at onset

0.82

0.73–0.92

0.001

0.83

0.71–0.97

0.016